Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORD | Q00796 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25897329 | 0.86 | APLNR (0.34) | — | |
| SCHEMBL18494814 | 0.79 | RXRA (0.32) | SORD | |
| SCHEMBL830187 | 0.74 | CYP1A2 (0.37) | SORD | |
| SCHEMBL25888171 | 0.74 | SORD (0.38) | SORD | |
| SCHEMBL12190563 | 0.73 | SORD (0.39) | SORD | |
| Ammonia Solution, Strong SCHEMBL28652832 | 0.73 | CYP1A2 (0.36) | — | |
| Ammonia Solution, Strong SCHEMBL11451734 | 0.71 | CYP1A2 (0.35) | — | |
| SCHEMBL19308850 | 0.71 | RXRA (0.31) | — | |
| SCHEMBL20415487 | 0.70 | SORD (0.38) | SORD | |
| SCHEMBL23015778 | 0.70 | TRPV3 (0.38) | SORD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159509-A1 | PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-10377695-B2 | Metabotropic glutamate receptor positive allosteric modulators (PAMS) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180194710-A1 | Metabotropic Glutamate Receptor Positive Allosteric Modulators (PAMS) and Uses Thereof | Sanford Burnham Prebys Medical Discovery Institute | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377695-B2 | Metabotropic glutamate receptor positive allosteric modulators (PAMS) and uses thereof | GRM3, GRM2, GRM1 | SORD 4853/4885 |
| US-20180194710-A1 | Metabotropic Glutamate Receptor Positive Allosteric Modulators (PAMS) and Uses Thereof | GRM3, GRM2, GRM1 | SORD 4853/4885 |
| US-20230159509-A1 | PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, PPM1D | SORD 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.